An in vitro model of EMT/MET using human near-normal and cancer-derived breast cell lines by Mafalda Maria Coelho Azevedo
  
 
 
 
 
 
 
 
 
An in vitro model of EMT/MET using human near-normal 
and cancer-derived breast cell lines 
 
Modelo in vitro de EMT/MET em linhas celulares de mama 
normal e de cancro de mama  
 
 
 
 
Mafalda Maria Coelho Azevedo 
 
 
Dissertação de Mestrado em Oncologia 
(especialidade: Oncologia Molecular) 
 
 
2012  
 2 
 
 
  
3 
 
 
  
 4 
 
 
  
5 
 
Mafalda Maria Coelho Azevedo 
 
 
An in vitro model of EMT/MET using human near-normal and cancer-
derived breast cell lines 
Modelo in vitro de EMT/MET em linhas celulares de mama normal e 
de cancro de mama  
 
 
 
 
 
 
Dissertação de Candidatura ao grau de 
Mestre em Oncologia (especialidade: 
Oncologia Molecular) submetida ao Instituto 
de Ciências Biomédicas Abel Salazar da 
Universidade do Porto. 
 
 
  
Orientador Doutora Carla Oliveira 
Categoria 1Investigadora, 
2Professora Afiliada 
Afiliação 1IPATIMUP, 2Faculdade 
de Medicina da 
Universidade do Porto 
Co-orientador Doutora Fátima Gärtner 
Categoria Professora Catedrática 
Afiliação Instituto de Ciências 
Biomédicas Abel Salazar 
da Universidade do Porto 
 6 
 
 
  
7 
 
ACKNOWLEDGMENTS  
 
Aos meus pais, que não poderiam deixar de vir em primeiro lugar. Muito Obrigada por 
todo o apoio, pelo suporte (financeiro também!), pela confiança que sempre depositaram 
em mim e por nunca duvidarem das minhas opções. Obrigada, principalmente a ti, Mãe, 
por aturares as minhas casmurrices e dramas, e me fazeres olhar para trás e pensar que 
estavas certa quando me dizias “Um dia ainda me vais dar razão”. Obrigada a ti, Pai, pela 
calma e tranquilidade que me transmites a cada momento. Obrigada pelos valores que 
me transmitiram e transmitem todos os dias, por me ensinarem a acreditar nas minhas 
capacidades e por me darem amor e carinho sempre. No fundo, Obrigada por serem os 
Melhores Pais do Mundo! 
Aos meus queridos irmãos, João e Carlinhos, que nunca me fizeram desejar ser filha 
única. A vocês obrigada por serem tão diferentes, mas tão iguais na forma como 
preenchem a minha vida. Obrigada por todos os momentos de risota, de brincadeiras de 
crianças, por crescermos e aprendermos juntos, pelas chatices e zangas que muitas 
vezes aconteceram, mas que nos tornaram pessoas melhores. Gosto muito de vocês e 
Obrigada por serem os Melhores Companheiros de Vida! 
À minha “Bó” e ao meu “Bú”, os meus segundos pais, de quem sempre recebi mimo e 
carinhos, ensinamentos de uma vida e muita sabedoria. Estão sempre presentes para 
ajudar no que for preciso, para trazer aquela ternura que só os avós conseguem ter. A 
vocês, o meu eterno Agradecimento por tudo! 
Às minhas meninas, Ana, Flávia, Moni e Su, por não serem da família, mas serem a 
família que eu escolhi. Já são tantos anos que é difícil recordar tudo aquilo que passamos 
e ultrapassamos, mas estivemos sempre juntas e isso é o mais importante. Não interessa 
estarem perto ou longe, estarão sempre comigo. Em memória a todos os nossos 
momentos de alegria, de risota, de cumplicidade e também a todos os momentos menos 
bons, um grande Obrigada! 
Ao grupo Carla Oliveira, do qual orgulhosamente faço parte: Joana Carvalho, Renata 
Carriço, Hugo Pinheiro, Patrícia Oliveira, Marta Teixeira Pinto, Daniel Ferreira, Denisa 
Mateus, Patrícia Pereira e Luís Maia. É um gosto trabalhar com vocês e sentir que há 
sempre alguém disposto a ajudar quando é preciso! Um Enorme Agradecimento a todos 
por me terem integrado, pelo apoio e pela animação de cada dia! 
 8 
 
À Patrícia, porque sem ela eu não estaria onde estou (apesar de no início achares que eu 
era uma “choca”!). Foste quem mais contribuiu para aquilo que sei hoje. Obrigada por me 
deixares fazer parte do teu trabalho, por depositares em mim tanta confiança e me 
ensinares a cada dia. Ainda me vais ensinar bioinformática! Obrigada por estares sempre 
disponível e por me teres ajudado tanto, principalmente nestas últimas semanas. A tua 
boa disposição constante e as piadas que me deixam sem palavras fazem com que todos 
os dias sejam melhores. Um Enorme Obrigada da tua primeira Mestranda! 
Um Obrigada à Joana. A tua ajuda sempre foi uma constante, desde os primeiros dias 
em que estive no IPATIMUP. Sempre foste paciente comigo e um grande apoio para 
mim! Obrigada por também tu teres contribuído tanto para a minha formação e teres 
sempre a palavra certa no momento certo! 
A todas as pessoas do Cancer Genetics “residentes” ou não: aqui deixo um GIGANTE 
Obrigada a todos (porque não quero esquecer-me de ninguém!). De uma forma ou de 
outra, todos contribuem diariamente para tornar os mês dias melhores. Sinto realmente 
que dentro daquele laboratório, não existe apenas um grupo de trabalho: existe uma 
família! Um Muito Obrigada por me ajudarem, por me fazerem rir e por tornarem este 
trabalho em algo indispensável para mim! 
Não poderia deixar de fora a Ritinha, sempre princesa! Andámos sempre par a par quase 
desde o primeiro dia. Obrigada por me teres ajudado sempre, mas também por todos os 
momentos de cusquice, de dicas sobre tudo e mais alguma coisa. Não percas essa tua 
alegria e energia contagiante! Obrigada por seres a melhor colega de mestrado de 
sempre e por termos partilhado este último ano :)  
Um Obrigada à Catarina Salgado (sempre divertida e impecavelmente combinada) e ao 
João Vinagre (por todas as longas esperas e boleias) que não são do CG, mas é como 
se fossem.  
Muito Obrigada à Doutora Fátima Gärtner por ter aceite co-orientar este trabalho sem 
reservas. 
E por fim, um Obrigada muito muito especial à Carla por me ter acolhido no grupo, por 
me ter dado a oportunidade de aprender e crescer cientificamente, pela ajuda constante e 
pela disponibilidade. Mas claro pela simpatia sempre presente, pelo apoio e 
disponibilidade. Um Imenso Obrigada! 
  
9 
 
 
  
 10 
 
  
11 
 
TABLE OF CONTENTS 
 
Acknowledgments ............................................................................................................. 7 
Abstract ...........................................................................................................................15 
Resumo ...........................................................................................................................17 
General Introduction ........................................................................................................21 
Novel avenues for cancer research ..............................................................................23 
EMT as a cancer-relevant biological pathway ...............................................................23 
EMT, TGF-β pathway and cancer.................................................................................25 
MET and cancer ...........................................................................................................26 
Aims and Thesis Outline ..................................................................................................31 
Material and Methods ......................................................................................................37 
Near-normal and cancer-derived breast cell culture .....................................................39 
RNA isolation and RT-PCR ..........................................................................................39 
Western Blot for E-cadherin, β-catenin and Fibronectin ................................................40 
Immunofluorescence for E-cadherin, β-catenin and Vimentin .......................................41 
RNA expression quantification .....................................................................................41 
Chapter One ....................................................................................................................45 
Aim ...............................................................................................................................47 
Results .........................................................................................................................47 
1. Phenotypical features and protein localization of epithelial and mesenchymal 
markers in several human breast cell lines ...............................................................47 
2. Quantification of gene expression of several epithelial and mesenchymal markers
 .................................................................................................................................49 
3. Expression of TGF-β receptors 1 and 2 ................................................................50 
Discussion ....................................................................................................................53 
Chapter Two ....................................................................................................................57 
Aim ...............................................................................................................................59 
Results .........................................................................................................................59 
 12 
 
1. Optimization of TGF-β1concentration able to induce EMT in MCF10A and MCF7AZ 
cell lines ....................................................................................................................59 
1.1 Cancer-derived cell line MCF7AZ .......................................................................59 
1.2 Near-normal cell line MCF10A ............................................................................61 
2. MET, the recovery of the epithelial phenotype? ....................................................63 
3. The establishment of a human in vitro EMT/MET model .......................................64 
Discussion ....................................................................................................................69 
Chapter Three..................................................................................................................73 
Aim ...............................................................................................................................75 
Results .........................................................................................................................75 
1. Dies1, a key gene for mouse embryonic stem cell differentiation vary along 
EMT/MET .................................................................................................................75 
Discussion and Unanswered Questions .......................................................................77 
Summary and Conclusions ..............................................................................................81 
Future Perspectives .........................................................................................................87 
References ......................................................................................................................91 
 
 
  
13 
 
 
  
 14 
 
  
15 
 
ABSTRACT 
 
Epithelial-Mesenchymal Transition (EMT) is a biological process involving the loss 
of epithelial characteristics and acquisition of mesenchymal features. Non-
pathological EMT occurs both during development (embryogenesis) as well as in 
adult individuals in situations of wound healing and tissue remodeling. Pathological 
EMT has been associated with cancer, in cells with de novo oncogenic ability and 
with genetic/epigenetic alterations underlying metastatic dissemination. While 
literature accumulates concerning EMT, few studies have focused on EMT’s 
reverse process, the Mesenchymal-Epithelial Transition (MET). This process is 
characterized by the down-regulation of mesenchymal markers and up-regulation 
of epithelial markers as well as of cell-cell adhesion. EMT and MET have relevant 
roles during cancer progression, as proposed by several authors. It has been 
suggested that cancer cells, derived from normal epithelial cells that have suffered 
a given set of genetic/epigenetic alterations, upon certain chemical cues from the 
microenvironment, could undergo EMT thus gaining mobility and detaching from 
the primary tumor. In addition, these now invasive cancer cells could then 
intravasate to the blood stream and reach a secondary site in the organism. The 
reversible nature of EMT would at this point be activated: cancer cells at the 
secondary site, could then undergo MET, regaining enough adhesion thus forming 
secondary tumors.  
 
Several molecules are able to induce EMT in vitro such as bone morphogenic 
proteins, platelet-derived growth factor and transforming growth factor beta. These 
molecules could be the chemical triggers to induce/allow EMT and consequently 
cancer progression in vivo: for example, cancer cells may secrete non-
physiological levels of TGF-β receptor ligands that both in a paracrine/autocrine 
manner may lead to tumor progression and metastasis.  
 
EMT/MET occurrence during cancer progression has been supported by several 
facts such as: presence of the same (epithelial) markers both in primary tumors 
and metastases from clinical samples; overexpression of mesenchymal markers in 
the invasive front of tumors. However, given that histological samples are a static 
scenario and EMT/MET is characterized by its dynamicity, in vitro models that 
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mimic these processes are key for understanding the biological alterations 
associated with EMT/MET. In vitro EMT/MET models can be the solution to 
uncover novel biological markers and regulatory mechanisms and hence novel 
therapeutic approaches. Therefore our aim was to establish novel EMT/MET in 
vitro models, using the cytokine TGF-β1 as an inducer, in near-normal and 
cancer-derived cell lines. 
In Chapter One of this Thesis we have tested several mammary cell lines aiming 
at selecting the best suited for an EMT induction. The expression of several 
epithelial and mesenchymal markers was assessed and MCF10A was the 
selected cell line. In Chapter Two of this Thesis we demonstrate the induction of 
EMT and MET in this cell line, thus creating a novel model that faithfully recreates 
the dynamic process of gain (EMT) and loss (MET) of mesenchymal markers and 
concomitant opposite variation of epithelial markers. These variations were 
confirmed by analyzing the RNA and protein expression of several markers. In 
Chapter Three of this Thesis, we have provided preliminary data on the 
comparison between the MCF10A EMT/MET model and another in house 
established EMT/MET model. We have compared the expression and regulation of 
the recently annotated gene Dies1 and observed that although with similar 
patterns of expression variation, the inherent regulatory mechanism is different in 
both models. This observation enhances the relevance of creating novel 
EMT/MET in vitro models and stresses the importance of the work described in 
this Thesis. 
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RESUMO 
 
A transição Epitelial-Mesenquimal (EMT) é um processo biológico que envolve a 
perda de características epiteliais e aquisição de características mesenquimais. 
EMT não patológica, ocorre tanto durante o desenvolvimento (embriogénese), 
assim como em indivíduos adultos em situações de cicatrização de feridas e 
remodelação do tecido. EMT patológica tem sido associada com cancro, tendo 
sido observada em células com capacidade oncogénica e com alterações 
genéticas/epigenética subjacentes disseminação metastática. Enquanto que 
vários estudos abarcam a temática da EMT, poucos se concentraram no processo 
inverso à EMT, a transição Mesenquimal-Epitelial (MET). Este processo é 
caracterizado pela diminuição na expressão de marcadores mesenquimais e 
aumento de marcadores epiteliais, bem como aumento da adesão entre células. 
EMT e MET têm papéis relevantes durante a progressão do cancro, como 
proposto por diversos autores. Tem sido sugerido que células cancerosas, 
derivadas de células epiteliais normais que tenham sofrido um conjunto de 
alterações genéticas/epigenéticas, mediante sinais químicos determinados a partir 
do microambiente, podem submeter-se a EMT ganhando assim mobilidade e 
destacando-se do tumor primário. Estas células cancerosas invasivas poderiam 
então intravasar para a corrente sanguínea e chegar a um local secundário no 
organismo. A natureza reversível da EMT seria neste momento ser activada: 
células cancerosas no local secundário, poderiam submeter-se a MET, 
recuperando suficiente adesão entre células que leve à formação de tumores 
secundários. Várias moléculas são capazes de induzir EMT in vitro, tais como 
"bone morphogenic proteins" (BMP), "platelet-derived growth factor" (PDGF) e 
"transforming growth factor beta 1" (TGF-β1). Estas moléculas podem ser 
responsáveis por induzir EMT e, consequentemente, permitir a progressão de 
cancro in vivo: por exemplo, as células cancerígenas podem segregar níveis não 
fisiológicos de ligandos de receptores TGF-β que, tanto de uma forma parácrina 
como autócrina, podem levar à progressão do tumor e formação de metástases. 
 
A ocorrência de EMT/MET durante a progressão do cancro tem sido apoiada por 
diversos factos, tais como a presença dos mesmos marcadores (epiteliais), tanto 
em tumores primários como em metástases e a sobre-expressão de marcadores 
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mesenquimais na frente invasiva de tumores. No entanto, dado que as amostras 
histológicas são um cenário estático e EMT/MET é caracterizada pelo seu 
dinamismo, modelos in vitro que imitam a esses processos são essenciais para a 
compreensão das alterações biológicas associadas com EMT/MET. Modelos in 
vitro de EMT/MET podem ser a solução para descobrir novos marcadores 
biológicos e mecanismos de regulação e, assim, novas abordagens terapêuticas. 
Portanto o nosso objectivo foi estabelecer novos modelos in vitro de 
EMT/MET, utilizando a citoquina TGF-β1 como um indutor, em linhas de 
células "normais" e de cancro. No Capítulo Um desta Tese testámos várias 
linhas celulares mamárias visando seleccionar a mais adequada para uma 
indução de EMT. A expressão de vários marcadores epiteliais e mesenquimais foi 
avaliada e MCF10A foi a linha celular seleccionada. No Capítulo Dois desta 
Tese, demonstrámos a indução de EMT e MET nesta linha celular, criando assim 
um novo modelo que recria fielmente o processo dinâmico de ganho (EMT) e 
perdas (MET) de marcadores mesenquimais e variação oposta concomitante de 
marcadores epiteliais. Estas variações foram confirmadas por análise da 
expressão de proteínas e de ARN de vários marcadores. No Capítulo Três desta 
Tese, apresentámos dados preliminares sobre a comparação entre o modelo 
EMT/MET em MCF10A e um outro estabelecido pelo nosso grupo. Comparámos 
a expressão e regulação de um gene recentemente anotado, Dies1, e 
observámos que, embora com padrões semelhantes de variação de expressão, o 
mecanismo regulador inerente é diferente em ambos os modelos. Esta 
observação reforça a relevância da criação de novos modelos in vitro de EMT / 
MET e salienta a importância do trabalho descrito nesta Tese. 
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GENERAL INTRODUCTION 
 
NOVEL AVENUES FOR CANCER RESEARCH 
In 2000, Hanahan and Weinberg published a review where they defined invasion and 
metastasis as hallmarks of cancer[1]. Although there was little knowledge on the 
mechanisms involved in these processes, the authors pointed that the activation of 
extracellular proteases and the alteration in the expression and function of cell-cell 
adhesion proteins, such as cadherins, and integrins were crucial for invasion and 
metastasis [1]. Later in 2011 another review from the same authors came out where they 
established a succession of cell-biologic changes: local invasion, intravasation into blood 
or lymphatic vessels, circulation of cancer cells through blood or lymph, extravasation, 
formation of micrometastases and finally, colonization [2]. The occurrence of metastatic 
spread of primary tumors is responsible for about 90% of cancer-related deaths[3]. For 
this reason during the past years, research concerning novel biological pathways/targets 
(in)activated during metastatic spread has dramatically increased, with several studies 
focused on the key biological process of Epithelial-Mesenchymal Transition (EMT). 
Epithelial and mesenchymal cells are the two major types of cells present in every animal 
tissue [4]. These two types of cells are the most common however their phenotypes are 
not static. Under certain conditions these cells convert between each other by two 
processes: the Epithelial-Mesenchymal Transition (EMT) and the reverse Mesenchymal-
Epithelial Transition (MET) [5]. Without these two processes the development of 
multicellular organisms would be impossible since they would not be able to evolve from 
the blastula stage of embryogenesis [6]. 
 
EMT AS A CANCER-RELEVANT BIOLOGICAL PATHWAY 
What is EMT and why has it been the focus of so many cancer research studies? The 
Epithelial-Mesenchymal transition is a biological process involving the loss of some 
characteristics of epithelial cells, marked by loss of “cobblestone-like” phenotype due to 
rearrangement of the cytoskeleton that leads to changes in cell shape and organization, 
loss of cell polarity and cell-cell adhesion, and the gain of mesenchymal features, marked 
by the “spindle-shaped” phenotype leading to increased invasion ability, migratory 
capacity, resistance to apoptosis and increased production of ECM components[7]. The 
activation of transcription factors and the altered expression of specific cell-surface 
proteins also happen when epithelial cells undergo EMT: loss or decrease of expression 
of epithelial markers, such as adherens junction proteins (E-cadherin, β-catenin), tight 
junction proteins (occludin, claudin) and cytokeratins[8]. Concomitantly, EMT also leads to 
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the gain or increase of the expression of mesenchymal markers, such as Fibronectin, 
Vimentin and N-cadherin [7,8,9,10]. 
EMT can be divided in three subtypes according to its function: type 1 EMT occurs during 
embryogenesis, for example during gastrulation leading to the formation of the ectoderm, 
mesoderm and endoderm; type 2 EMT is associated with wound healing and tissue 
remodeling after a noxious event or injury in adult individuals; and type 3 EMT is directly 
associated with cancer and occurs in cells with de novo oncogenic ability and with several 
genetic and epigenetic alterations leading to metastatic dissemination [10]. 
The dynamic characteristic of the Epithelial-Mesenchymal Transition makes it impossible 
to be identified according to the parameters defined by pathologists [6,11]. Due to this, it 
took a long time to be accepted as important for tumor progression and both EMT and 
MET are now closely associated with invasion and metastasis [6]. In fact, in vitro and in 
vivo studies have revealed several common features between EMT and cancer 
progression: 1) invading carcinoma cells, thought to be responsible for invasion and 
metastasis, can display a mesenchymal phenotype and express mesenchymal markers 
such as Vimentin[12]; 2) tumor budding in colorectal cancer, a phenomenon by which 
tumor cells in the invasion front become detached and move towards the stroma in a 
EMT-like fashion[7]; 3) in some types of colon cancer, single migratory cells have been 
observed detaching from the primary tumor with concomitant loss of E-cadherin 
expression [7,13]; 4) in cervical cancer, tumor cells located in the invasive front have been 
shown to, besides displaying loss of E-cadherin, possesses increased Vimentin 
expression; 5) expression of many EMT drivers, such as Snail and Slug, in breast, 
colorectal and ovarian cancer, have been shown to be significantly correlated with poor 
clinical outcome [14]. 
However, David Tarin (2005) claims that EMT experiments in vitro are extremely artificial 
because cells cultured both in a two or three dimensional environments are not 
representative of vascular, endocrine or neurologic dynamism. The author also refers that 
the classification of cell lines as epithelial or mesenchymal is commonly based on cell 
shape and that the evaluation of one or a few markers is not enough to assume the 
occurrence of EMT, i.e., to conclude that a cell population has completely changed its 
whole-scale gene expression programming [11]. 
Even so, to extend the knowledge on these processes, there has been an attempt to 
establish several in vitro models from different origins (normal and cancer cell lines) that 
undergo partial or complete EMT in order to follow the dynamism of the transition [6]. In 
an in vitro condition, EMT can be induced using several extracellular factors such as: 
transforming growth factor-β (TGF-β), bone morphogenetic proteins (BMPs), Wnt, Notch 
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ligands, hepatocyte growth factor (HGF), platelet-derived growth factor (PDGF) and 
fibroblast growth factor (FGF) [15].  
 
EMT, TGF-β PATHWAY AND CANCER 
TGF-β1is a cytokine that is produced in our organism regulating proliferation and 
differentiation, involved in immune suppression, apoptosis, angiogenesis and also related 
to EMT during carcinogenesis [16,17,18].  
TGF-β1 binds to membrane serine-threonine kinase receptor type 2 that recruit the type 1 
receptor (TGFβR2 and TGFβR1, respectively) and activates its kinase activity by 
phosphorylation. The intracellular signaling is mainly transduced through Smad proteins; 
however it can also be a non-Smad signaling. After Smad2 or Smad3 are phosphorylated 
by TβRI, they associate with Smad4 and are translocated to the nucleus to modulate gene 
transcription. The receptors of TGF-β1 can also activate Erk, JNK, p38 MAP kinases, PI3 
kinase and small GTPases like Cdc42 and Rac[15,16,18,19,20]. 
There has been much interest in studying the dual behavior of TGF-β during cancer 
progression, also known as “TGF-β Paradox”. In an earlier stage, Smads regulate the 
expression of many genes including c-myc, which is repressed and p21 and p15 that are 
induced. These genes promote the arrest of cell cycle in G1 phase preventing cells to 
divide [16]. However, it is very common the loss of this antiproliferative effect of TGF-β in 
cancer, e.g. due to mutations in components of the signaling cascade [18]. It has been 
observed resistance to the antiproliferative effect of TGF-β in head and neck squamous 
cell carcinomas, lung cancer, gastric cancer, colon cancer, pancreatic cancer, ovarian 
cancer and in some recurrent breast cancers [19].  
With the aim to better understand the response to TGF-β1 and to determine the frequency 
of success in inducing EMT in vitro using TGF-β1, Brown and colleagues (2003) used an 
extended panel of 18 established normal and tumorigenic cell lines of human (epidermoid, 
breast, lung, pancreas and prostate) and mouse (epidermoid, mammary gland and 
kidney) origin and primary cultures of two human mammary epithelial cells. All cells were 
treated with the same amount of TGF-β1 (5ng/ml) for 48h. At the end of the experiments 
only NMuMG and MCT cell lines (a normal murine mammary gland epithelial and a 
murine proximal tubular cell line, respectively) underwent TGF-β1 mediated EMT, which 
was confirmed by the expression of E-cadherin, Zona Occludens 1 (ZO-1) and the 
formation of actin stress fibers. The authors have also seen formation of actin stress fibers 
in MCF10A cells (a normal human mammary gland epithelial cell line) but only after 6 
days of culturing cells with TGF-β1. With this study, Brown et al. (2003) refuse the 
hypothesis that cells need to gain resistance to the antiproliferative effects caused by 
TGF-β since it was observed that these cells exhibited decreased S-phase of cell cycle 
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and underwent EMT [19]. Unlike these results, there are some reports of TGF-β induced 
EMT in vitro with different cell lines, e.g., established from prostate tumors [21] or non-
tumorigenic mouse mammary cells [22]. 
The possible origin of EMT-inducing TGF-β pathway ligands has been recently explored 
by several groups. Moustakas et al (2002), suggest that cancer cells can start secreting 
non-physiological levels of TGF-β receptor ligands affecting not only their differentiation in 
an autocrine manner, but also the surrounding cellular environment in a paracrine 
manner, which leads to tumor progression and consequent metastasis [16].Another study, 
by Labelle et al(2001) has shown that contact between tumor cells and platelets can be 
sufficient to induce an EMT-like transition and invasive behavior in vitro, and to stimulate 
metastatic seeding in the lung in vivo. If we take into account that cancer cells, which are 
able to intravasate,can/will be in contact with platelets, the results of Labelle et al(2011) 
suggest a later acquisition of the mesenchymal phenotype, i.e., after leaving the primary 
tumor microenvironment. Therefore, cancer cells may/had to intravasate as epithelial cells 
via leaky blood vessels or via collective invasion mechanisms [23]. To confirm this 
hypothesis, the authors found expression of epithelial markers such as epithelial cell 
adhesion molecules and cytokeratins in circulating tumor cells, which suggest that EMT 
may be not crucial to access the blood flow. Labelle et al(2011)also collected results 
showing that the observed prometastatic effects were largely mediated via the activation 
of the TGF-β pathway. In addition, upon either TGF-β pathway abrogation in tumor cells 
or TGF-β expression inhibition in platelets there was no induction of EMT. This clearly 
indicates that platelets are an important source of this growth factor for tumor cells in 
circulation [23]. 
 
MET AND CANCER 
Unlike EMT that has been extensively studied, the interest of the scientific community in 
understanding the reverse process, MET, is relatively recent. The Mesenchymal-Epithelial 
Transition is characterized by the down-regulation of mesenchymal markers and 
transcriptional factors such as N-cadherin, Zeb1 and Snail and also by the up-regulation 
of epithelial markers such as E-cadherin and Occludin. During MET, cells re-gain the 
polarity and establish more cell-cell adhesion contacts [4,6]. In 2010, Li et al found that it 
was possible to transform fibroblasts, which are a product of EMT, into induced pluripotent 
stem cells (iPSCs), via MET by suppressing pro-EMT factors, e.g., blocking TGF-β 
signaling. This was particularly interesting because it enabled the authors to unravel a key 
cellular mechanism to induce pluripotency that can be useful to produce pluripotent stem 
cells from an individual that are compatible with his/her own immune system [24]. 
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Korpal et al (2011) have shown that the overexpression of miR200 family is associated 
with high risk of metastasis in breast cancer due to the ability to regulate MET and 
metastatic colonization in mouse models [25]. The findings of the authors indicate that 
both EMT and MET have an important role in different stages of metastatic colonization: 
while EMT is accompanied by low levels of miR200s, promote invasion and intravasation; 
MET and high levels of mirR200s are needed for successful colonization of distant organs 
[25]. These results are in line with Thiery's hypothesis suggesting MET as a necessary 
event that allows the establishment of metastases [6]. 
 
In conclusion, and to dissect whether these mechanisms have a parallel in clinical 
samples of cancer patients, it is mandatory to confirm the occurrence of EMT 
and/or MET in primary cancer and metastases samples. If that is the case, the 
identification of in vivo EMT/MET may provide the grounds to develop novel 
therapeutic approaches: on one hand by trapping disseminated cancer cells in a 
latent state of micrometastases, thus inhibiting the development of solid tumor 
metastases, and; on the other hand by targeting and preventing the re-
epithelialization process which appears to be relevant for metastases 
establishment [26]. 
The creation of in vitro models that recreate EMT/MET are powerful tools as a first 
step to study these processes and this has been the major goal of this Thesis. 
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AIMS AND THESIS OUTLINE 
 
The Epithelial to Mesenchymal Transition (EMT) hypothesis suggests that cancer 
epithelial cells, at the periphery of the tumor, receive signals from the surrounding stroma, 
thus acquiring properties that enable them to become motile and invade. Some recent 
reports also suggest that although EMT may drive the initial steps of the metastasis 
process, a reversion of the mesenchymal phenotype back to epithelia (MET) of malignant 
cells is needed to facilitate the establishment of macroscopic metastases. This has been 
proven essentially by using clinical samples of primary tumors and metastases from 
several cancer types, however the dynamic transition processes are difficult to assess. 
Therefore, the global aim of this study was to establish a dynamic in vitro model of 
EMT/MET using human near-normal and cancer-derived breast cell lines, in order to 
better understand the alterations that occur during EMT and MET. Several molecules 
exist that have been shown to be able to induce EMT in vitro. Many studies have been 
published which have used the cytokine TGF-β1 as an in vitro EMT inducer. Therefore, in 
order to accomplish our global aim, we have elected this cytokine to establish our 
EMT/MET model. 
 
The work enclosed in this Thesis has been divided in three distinct chapters. Each chapter 
has been subdivided into three sections: aims, results and discussion. Given that similar 
techniques were applied in all three chapters, this Thesis also includes a general 
MATERIAL AND METHODS section. Concerning the work described in each chapter: 
 
 In CHAPTER ONE, we characterized several breast cell lines (near-normal and 
cancer-derived) aiming at selecting those with endogenous epithelial features as 
models for in vitro TGF-β1-induction of EMT/MET. 
 
 In CHAPTER TWO, the major focus was the generation of an EMT/MET in vitro 
model using the cell lines selected in Chapter One and TGF-β1 treatment. This 
Chapter enclosed two tasks: 1) finding the best suited concentration of TGF-β1 to 
induce EMT in vitro in each selected cell line and; 2) reversing EMT by removal of 
TGF-β1, to obtain a near-epithelial phenotype through MET. To confirm the 
occurrence of both EMT and MET, we characterized a panel of epithelial and 
mesenchymal markers at RNA and protein levels. 
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 In CHAPTER THREE, we aimed at demonstrating the relevance of TGF-β1-induced 
EMT/MET models in the study of cellular regulatory functions. We herein present 
interesting results concerning the EMT/MET model established in the present work 
and a previous similar model (EpH4 EMT/MET in vitro model). 
 
 
Integrated data from all chapters was summarized in the SUMMARY AND CONCLUSIONS 
section of this Thesis. Planned/ongoing applications of the established in vitro EMT/MET 
model were described in the FUTURE PERSPECTIVES section of this Thesis. 
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MATERIAL AND METHODS 
 
NEAR-NORMAL AND CANCER-DERIVED BREAST CELL CULTURE 
HB4a cells was derived from normal breast luminal cells and were cultured in RPMI 
(Invitrogen, Oregon, USA) culture medium supplemented with fetal bovine serum (10%, 
Lonza, Switzerland), penicillin-streptomycin (1%, Invitrogen, Oregon, USA),hydrocortisone 
(5µg/ml, Sigma-Aldrich, Missouri, USA), recombinant human insulin (5 µg/ml, Invitrogen, 
Oregon, USA), Cholera toxin (25 ng/ml, Sigma-Aldrich, Missouri, USA). 
226L cell line, a normal epithelial mammary cell line was cultured in DMEM and F12 (1:1, 
Invitrogen, Oregon, USA) supplemented with fetal bovine serum (10%, Lonza, 
Switzerland), penicillin-streptomycin (1%, Invitrogen, Oregon, USA), hydrocortisone (1 
µg/ml, Sigma-Aldrich, Missouri, USA), recombinant human insulin (5 µg/ml, Invitrogen, 
Oregon, USA), Cholera toxin (20 ng/ml, Sigma-Aldrich, Missouri, USA) and recombinant 
human epidermal growth factor (20 ng/ml, Sigma-Aldrich, Missouri, USA). 
MCF10A cells derived from mammary gland were cultured in DMEM and F12 (1:1, 
Invitrogen, Oregon, USA) supplemented with horse serum (5%, Lonza, Switzerland), 
penicillin-streptomycin (1%, Invitrogen, Oregon, USA), hydrocortisone (500 ng/ml, Sigma-
Aldrich, Missouri, USA), recombinant human insulin (40 µg/ml, Invitrogen, Oregon, USA), 
Cholera toxin (100ng/ml, Sigma-Aldrich, Missouri, USA) and recombinant human 
epidermal growth factor (20 ng/ml, Sigma-Aldrich, Missouri, USA). 
MCF 7AZ breast cancer cell line was cultured in DMEM and F12 (1:1, Invitrogen, Oregon, 
USA) supplemented with fetal bovine serum (10%, Lonza, Switzerland) and penicillin-
streptomycin (1%, Invitrogen, Oregon, USA). 
All cell lines were cultured at 37ºC and 5% CO2.All cell lines were kindly provided by 
Joana Paredes (Cancer Genetics Group, IPATIMUP). 
When referred, mesenchymal cells were obtained by supplementing the normal culture 
medium with Transforming Growth Factor β1 (TGF-β1, Sigma-Aldrich, Missouri, USA). 
Transient state cells were obtained by replacing the  TGF-β1 enriched medium by normal 
culture medium. 
 
RNA ISOLATION AND RT-PCR 
RNA was isolated from the four cell lines using the mirVana miRNA Isolation Kit 
(Invitrogen, Oregon, USA), following the kit’s instruction manual. Complementary DNA 
(cDNA) was obtained from 1 µg of RNA of each cell line and random primers, for 10 
minutes at 70ºC and 2 minutes at 4ºC. The enzyme SuperScript Reverse Transcriptase II 
(Invitrogen, Oregon, USA) was used for cDNA synthesis. The reaction occurred for 60 
minutes at 37ºC. PCR reaction was performed using 50 ng of cDNA (forward and reverse 
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primers described in Table 1) and Taq Polymerase (GE Healthcare, USA). PCR was done 
using the following conditions: 5 minutes at 94ºC, 30 cycles of 30 seconds at 94ºC, 30 
seconds at 60/56ºC (depends on the pair of primers used), 2 minutes at 72ºC and for last 
10 minutes at 72ºC. 
 
Table 1 – Primers sequence of TGF-β receptors 1 and 2 and of GAPDH. 
 
TGFβR1  
   Forward GCAAAGGTCGATTTGGAGAAGT 
   Reverse CTGCCAGTCCTAAGTCTGCAAT 
TGFβR2  
   Forward GGAGTACCTGACGCGGCATG 
   Reverse GGTGGTTGAGCCAGAAGCTG 
GAPDH  
   Forward TCAAGGCTGAGAACGCGAAG 
   Reverse AGAGGGGGCAGAGATGATGA 
 
 
WESTERN BLOT FOR E-CADHERIN, β-CATENIN AND FIBRONECTIN 
HB4a, 226L, MCF10A and MCF7AZ cells were washed with PBS and then lysed in cold 
PBS containing 1% Triton X-100 (Sigma-Aldrich, Missouri, USA), 1% NP40 (Sigma-
Aldrich, Missouri, USA), protease inhibitor cocktail (Roche, USA) and phosphatase 
inhibitor cocktail (Sigma-Aldrich, 1:100 dilution). Total protein was quantified using 
Bradford Protein Assay (Bio-Rad). 
Equal amounts of total cell protein lysates from each cell line were subjected to 30% SDS-
PAGE electrophoresis and then transferred to nitrocellulose membranes. After blocking 
with 5% nonfat milk, the membranes were incubated with primary antibodies against: E-
cadherin (24E10, Cell Signalling, MA, USA); β-catenin (purified mouse anti-β-catenin, 
610153, BD Transduction Laboratories) and Fibronectin (sc-69681, Santa Cruz 
Biotechnology). Next, menbranes were washed four times with PBS Tween solution, 
followed by incubation with horseradish peroxidase-linked secondary antibody for blot 
analysis. Blots were also probed with anti-actin antibody (Santa Cruz Biotechnology) or 
anti-tubulin antibody (Sigma-Aldrich) for loading control analysis. 
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IMMUNOFLUORESCENCE FOR E-CADHERIN, β-CATENIN AND VIMENTIN 
HB4a, 226L, MCF10A and MCF 7AZ cells were grown in normal medium in 9mm Petri 
plates with coverslips (Becton Dickinson Labware, Franklin Lakes, NJ, USA) inserted. 
After adequate cell growth, the culture medium was removed and the cells were washed 
twice with PBS supplemented with calcium (1:100). Cells were fixed in ice-cold methanol 
for 10 minutes. Prior to incubation during 1 hour with a mixture of primary antibodies the 
cells were blocked with 5% bovine serum albumin for 30 minutes. The primary antibodies 
used were: anti-E-cadherin (24E10, Cell Signalling, MA, USA); anti-β-catenin (purified 
mouse anti-β-catenin, 610153, BD Transduction Laboratories); anti-Vimentin (Monoclonal 
mouse anti-Vimentin, MO725, Clone V9, DakoCytomation). After four washes with PBS, 
secondary antibody anti-rabbit or anti-mouse Alexa 488 or Alexa 594 (Invitrogen, Oregon, 
USA), were incubated for 1 hour at room temperature in the dark. Coverslips with cells 
were washed six times with PBS and mounted using Vectashield mounting medium 
containing DAPI (Vector Laboratories Inc, CA, USA). Images were taken with a Zeiss 
Imager.Z1, AxioCamMRm. 
 
RNA EXPRESSION QUANTIFICATION 
RNA was isolated from the four cell lines using the mirVana miRNA Isolation Kit 
(Invitrogen, Oregon, USA), following the kit’s instruction manual. Approximately 1000 ng 
of total RNA were reverse transcribed to single stranded cDNA using Superscript II 
Reverse Transcriptase and random hexamer primers (Invitrogen, Oregon, USA). 
Quantitative Real-Time-PCR (qRT-PCR, using a ABI Prism 7000 Sequence Detection 
System) was carried out in triplicates using source RNA, using TaqMan Gene Expression 
Assays (Applied Biosystems, California, USA) or PrimeTime qPCR Assays (Integrated 
DNA Technologies, Iowa, USA) for the following target genes: human 
CDH1(Hs.PT.49a.3324071), Ocln (Hs.PT.49.14927371), CDH3(Hs00999918_m1), FN1 
(Hs.PT.47.1565512), Vim (Hs.PT.47.14705389), CDH2 (Hs.PT.49.15618412),Zeb2 
(Hs.PT.47.1778946), Dies1 (Hs00735289_m1), Id2 (Hs00747379_m1) and Id3 
(Hs00171409_m1).. The endogenous control was human GAPDH (Hs02758991_g1). 
Data was analyzed by the comparative 2(-ΔΔCT) method. We performed t-test to evaluate 
the significance of the data obtained from the quantification of mRNA expression. 
 
DIES1 METHYLATION STATUS ANALYSIS 
DNA from a MCF10A E and TS cells was extracted using the kit Invisorb Spin Tissue Mini 
Kit following the manufacturer’s instructions (STRATEC Molecular, Berlin, Germany). 
Approximately 300 ng of DNA from each cell type was then subjected to complete bisulfite 
conversion and subsequent clean-up using the Epitect  Bissulfite Kit following 
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manufacturer’s instructions (Qiagen, Hilden, Germany). Bisulfite treated DNA was 
amplified using primers flanking the predicted Dies1 promoter. This prediction was based 
on the classical approach of analyzing the bioinformatically predicted CpG islands within 
the gene’s locus, given the known association between CpG islands and promoter 
regions. The criteria used for CpG island prediction was as follows: 1) genomic area with 
>500 bp; 2) a percentage of CG>55 and; 3) the observed/expected CpG 
dinucleotides>0,65 (CpG Island Searcher Website). Concerning human Dies1 the 
predicted CpG island was located at chromosome 10:73533894-73534693 and the CpG 
sites analyzed were located at chromosome 10:73534292-73534425. The bisulfite PCR 
products were sequenced for methylation status determination.  
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CHAPTER ONE 
Characterization of near-normal and cancer-derived cell lines 
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AIM 
 
The objective of this part of the work was to characterize several breast cell lines(near-
normal and cancer-derived) aiming at choosing those with the most adequate features to 
be used as an in vitro TGF-β1-induced EMT/MET model. We have assessed the 
expression (RNA and/or protein) of a set of epithelial and mesenchymal markers to 
characterize a series of cell lines using several techniques such as quantitative real-time-
PCR (qRT-PCR), immunofluorescence, western blot (WB) and reverse transcriptase-PCR 
(RT-PCR). The selected cell line(s) would have to display key epithelial features: 1) 
classical cobble-stone morphology; 2) expression of epithelial markers; 3) 
absent/diminished expression of mesenchymal markers;4) expression of TGF-β receptors 
and; 5) literature supporting the feasibility of EMT induction. 
 
RESULTS 
 
1. PHENOTYPICAL FEATURES AND PROTEIN LOCALIZATION OF EPITHELIAL AND MESENCHYMAL 
MARKERS IN SEVERAL HUMAN BREAST CELL LINES 
We started by characterizing three different near-normal cell lines of human mammary 
origin. HB4a cell line derives from normal breast luminal cells[27].Figure 1, in bright field 
microscopy images, displays the general morphology of a sub-confluent culture of the 
human HB4a cell line. As morphology is not enough to characterize a cell line as 
epithelial, we proceeded by characterizing the protein expression/localization by 
immunofluorescence of two known epithelial markers, E-cadherin and β-catenin, as well 
as of a mesenchymal marker, Vimentin. In Figure 1, in the column correspondent to HB4a 
cells, it is possible to observe that both E-cadherin and β-catenin localized at the cell 
membrane while no expression of Vimentin was detected. 
The normal human epithelial mammary 226L cell line [28] morphology can be also 
observed in Figure 1, in bright field microscopy images. These cells exhibited an epithelial 
phenotype as well as E-cadherin and β-catenin localization at the cell membrane, and 
residual expression of Vimentin. 
The third of the near-normal human cell lines chosen was MCF10A cell line, which derived 
from human fibrocystic mammary tissue [29]. Its epithelial morphology is present in the 
bright field microscopy images (Figure 1) and both E-cadherin and β-catenin were 
expressed at the cell membrane. These cells displayed considerable expression of 
Vimentin when compared to other cell lines, an observation confirmed in multiple 
biological replicas. 
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We also used a cancer-derived cell line, MCF7AZ, which is a variant of MCF7 human 
mammary carcinoma cell line[30]. These cells displayed an epithelial morphology as 
observed in the bright field microscopy images (Figure 1). MCF7AZ presented E-cadherin 
and β-catenin expression located at the cell membrane and the expression of Vimentin 
was absent, as it is possible to observe in the immunofluorescence images (Figure1). 
 
Figure 1 –Characterization of three near-normal and one cancer-derived breast cell lines. 
Bright field microscopy images exhibit the epithelial phenotype of the parental cell lines (100x). All 
cell lines displayed an epithelial morphology with a typical cobble-stone phenotype. 
Immunofluorescence was performed for the four cell lines using antibodies for epithelial markers 
(E-cadherin (green), β-catenin (red)) and mesenchymal markers (Vimentin (red)). The white scale 
bar corresponds to 50 µm. All cell lines displayed E-cadherin and β-catenin expression at the cell 
membrane. Vimentin expression was detected in 226L and MCF10A. 
 
Using total protein lysates extracted from all four cell lines we assessed the expression 
profile of the abovementioned epithelial markers, as well as of Fibronectin, a 
mesenchymal marker (by WB).We did not assess Vimentin by WB and Fibronectin by 
immunofluorescence due to technical difficulties. All cell lines expressed E-cadherin and 
β-catenin as it was expected and only 226L expressed Fibronectin (Figure 2A-C). After 
adequate normalization to actin (endogenous control) we observed that MCF7AZ 
displayed the highest levels of total E-cadherin, while all other cell lines displayed similar 
levels (Figure 2D). Concerning β-catenin, all cell lines displayed similar levels (Figure 
2D). 
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Figure 2 – Protein expression of epithelial and mesenchymal markers across all selected 
cell lines (one biological replicate). Results of the Western Blot performed for E-cadherin (A), β-
catenin (B), Fibronectin (C) using total protein lysates extracted from HB4a, 226L, MCF10A and 
MCF7AZ cell lines. D. Quantification of the bands present in A, B and C. All cell lines expressed 
both epithelial markers and only 226Lcell line expressed Fibronectin. 
 
2. QUANTIFICATION OF GENE EXPRESSION OF SEVERAL EPITHELIAL AND MESENCHYMAL 
MARKERS 
 
For each cell line we collected total RNA to evaluate and quantify the expression of 
several genes known to be markers of epithelial or mesenchymal cells. For this, we used 
the quantitative real-time-PCR (qRT-PCR) technique, not aiming at comparing the 
expression levels between samples, rather observing whether each gene was expressed 
or not. 
The epithelial markers evaluated were: 1)CDH1, which encodes for E-cadherin and was 
detected in all cell lines(Figure3A); 2) Ocln, which encodes for Occludin, a tight-junction 
component, which was also detected in all cell lines (Figure3B) and; 3) CDH3, which 
encodes for P-cadherin, again expressed in the four cell lines (Figure 3C). 
Next, we evaluated the RNA expression of three mesenchymal markers: 1) FN1, which 
encodes for Fibronectin and was expressed in 3 out of 4 cell lines, being MCF10A the 
only cell line that was negative for the expression of this gene (Figure 3D); 2) Vim, which 
encodes for Vimentin, was only expressed in 226L and MCF10A cell lines (Figure 3E) 
and; 3) CDH2, which encodes for N-cadherin, was expressed in all cell lines (Figure 3F). 
In addition, we evaluated the RNA expression of the EMT inducer Zeb2, which displayed 
a residual expression in the MCF10A cell line. 
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Figure 3 – mRNA expression of epithelial and mesenchymal markers across all selected cell 
lines (one biological replicate).  Expression levels of epithelial markers: CDH1 (A), Ocln (B) and 
CDH3 (C); Expression levels of mesenchymal markers: FN1 (D), Vim (E) and CDH2 (F). 
Expression levels of the EMT inducer Zeb2 (G). Expression pattern of the assessed markers led to 
the choice of MCF10A for EMT/MET induction (highlighted by a red box). 
 
3. EXPRESSION OF TGF-β RECEPTORS 1 AND 2 
One of the goals of this part of the work was also to choose the cell line(s) with 
operational TGF-β receptors 1 and 2 (TGFβR1, TGFβR2), crucial for TGF-β pathway 
activation. The absent expression of one of the TGF-β receptors would be an exclusion 
criterion. Therefore, we performed a RT-PCR to confirm the expression of TGFβR1 and 
TGFβR2. In Figure 4we can observe that all four cell lines expressed both receptors. All 
cell lines studied had the phenotypical features and E-cadherin/β-catenin 
expression/localization expected for epithelial cell lines (Table 1). In addition, similar 
results were observed concerning epithelial markers’ gene expression. Concerning the 
mesenchymal marker Fibronectin, we observed: 1) protein expression was only detected 
in 226L although its RNA was detected also in HB4a and MCF7AZ; 2) neither protein nor 
RNA expression was detected in MCF10A cell line, an observation crucial for the cell line 
selection process (Table 1).  
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Figure 4 –TGFβR1 and TGFβR2 expression in HB4a, 226L, MCF10A and MCF7AZ cell lines. 
NC refers to the negative control. All cell lines expressed both receptors. 
 
In fact, we selected the MCF10A cell line for our next studies given that: 1) previous 
studies in our group have already emphasized the relevance of FN1 as a key 
mesenchymal marker in an established in house mouse EMT/MET in vitro model [22]; 2) 
past studies have shown that it is possible to induce EMT in MCF10A, unlike HB4a and 
226L for which no studies have been published.  In addition, we have also selected the 
MCF7AZ cell line for our next studies given that it is cancer-derived and could be viewed 
as a pathological counterpart of the MCF10A cell line. 
 
Table 1 – Summary of the characterization performed on the four selected cell lines. 
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DISCUSSION 
 
In this part of the study we characterized a series of cell lines with the goal of choosing at 
least one with the adequate features to be used in an in vitro human TGF-β1-induced 
EMT/MET model.  
All cell lines that were studied had the classical features of epithelial cells: classical 
cobble-stone morphology; expression of E-cadherin and β-catenin (RNA and/or protein 
level)at the cell membrane; expression of TGF-β receptors, and; expression, at the RNA 
level, of a panel of epithelial markers (Table 1). 
Despite the presence of epithelial markers, all cell lines expressed at least one 
mesenchymal marker (Table 1): HB4a presented expression of FN1 and CDH2; 226L 
displayed FN1, Vim and CDH2 expression; MCF7AZ expressed FN1 and CDH2 and; 
MCF10A exhibited Vim and CDH2. Concerning Vim/Vimentin expression in MCF10A cell 
line, this result was confirmed in distinct biological replicas and it has also been reported 
in the literature[31]. This cell line also displayed residual levels of Zeb2, again in 
agreement with current literature [32]. Nevertheless, MCF10A cell line is currently 
considered a bonafide model of an epithelial cell line, thus fulfilling the requisites to be 
used as a model for TGF-β1-induced EMT/MET model. Therefore, we decided to choose 
MCF10A cell line to establish our in vitro model of EMT/MET. In addition, there have been 
studies reporting that EMT can be efficiently induced in vitro using MCF10A cells cultured 
with TGF-β1-enriched-medium [19,33,34]. Concerning HB4a and 226L cell lines there are, 
currently no studies that have used these cell lines for EMT induction. In addition, both cell 
lines display FN1 expression, a key mesenchymal marker [22]. Therefore, we did not 
select any of these cell lines for the next steps of this study. 
Due to the connection of EMT with tumor progression, as discussed in General 
Introduction, it would be interesting to have a pathological counterpart for the induction of 
EMT. As the cancer-derived cell line MCF7AZ fulfills the criteria established for the 
definition of an epithelial cell line, we decided to include this cell line in the experiments of 
Chapter Two. 
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CHAPTER TWO 
Induction of mesenchymal phenotype 
Recovery of epithelial phenotype 
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AIM 
 
The major focus of this part of the work was to induce EMT using TGF-β1and to be able to 
reverse the process, thus creating a dynamic EMT/MET in vitro model. To accomplish this 
aim, we have used the cell lines selected in the previous Chapter, MCF10A and MCF7AZ. 
The first task was to find the best-suited concentration of TGF-β1 to induce EMT in vitro in 
both cell lines. The second task was to reverse EMT, thus inducing MET by allowing cells 
that have undergone EMT to re-acquire an epithelial phenotype. 
To confirm the occurrence of both EMT and MET, we have characterized a panel of 
epithelial and mesenchymal markers (RNA and/or protein) in each step of these 
transitions using techniques, such as qRT-PCR, immunofluorescence and WB. 
 
RESULTS 
 
1. OPTIMIZATION OF TGF-β1CONCENTRATION ABLE TO INDUCE EMT IN MCF10A AND 
MCF7AZ CELL LINES 
To test the best concentration of TGF-β1 to induce EMT we have cultured both cell lines 
with normal culture medium enriched with 10 or 20 ng/ml of TGF-β1. With this experiment 
we aimed at observing alterations on: 1)the morphology of cells; 2) protein 
expression/localization by immunofluorescence and; 3) RNA expression by qRT-PCR. 
 
1.1 Cancer-derived cell line MCF7AZ 
When cultured in normal medium enriched with 10 or 20 ng/ml of TGF-β1, MCF7AZ cells 
did not lose the epithelial morphology, represented in the bright field microscopy images 
of Figure 1. In the co-immunofluorescence images of Figure 1 it is possible to observe 
that the cell membrane expression of E-cadherin was not lost and that Vimentin did not 
form fibers, as it was expected if these cells had undergone classical EMT.  
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Figure 1 – Effect of distinct TGF-β1 concentrations on EMT induction in MCF7AZ cell line. 
The cells were treated with different concentrations of TGF-β1 (0, 10 and 20 ng/ml) in order to 
induce EMT. For each condition is represented a bright field microscopy image (100x) and a co-
immunofluorescence for E-cadherin (green) and Vimentin (red). No alterations were observed with 
any of the distinct TGF-β1 concentrations tested. The white scale bar corresponds to 50 µm. 
 
Next, we evaluated the expression at theRNA level of key epithelial and mesenchymal 
markers by qRT-PCR on MCF7AZ cells cultured under varying TGF-β1 concentrations. 
We observed that the expression of CDH1 significantly decreased when MCF7AZ cells 
were cultured with both 10 and 20 ng/ml of TGF-β1 (p-value=6,30E-06 and 4,16E-05 in 
comparison with no TGF-β1 added, Figure 2A). However, the mesenchymal markers did 
not indicate the occurrence of EMT: 1) CDH2 expression was not detected in any 
condition (Figure2B); 2) Vim significantly decreased even when the highest concentration 
of TGF-β1was added (p-value=2,02E-05 and 2,58E-05 in comparison with no TGF-β1 
added, Figure2C) and; 3)FN1 also had a significant decrease in expression however only 
when the 20 ng/ml of TGF-β1 were added (p-value=2,59E-02 in comparison with no TGF-
β1 added, Figure2D). Interestingly, both in the case of CDH1 and Vim expression, 
MCF7AZ cells subjected to TGF-β1 treatment displayed significant differences when 
comparing the two concentrations tested: with 20ng/ml of TGF-β1, the levels of CDH1 and 
Vim where superior to those detected with 10 ng/ml of TGF-β1, although still significantly 
lower than those observed in the absence of this cytokine (p-value=1,25E-02 for CDH1 
and 1,54E-02 for Vim when comparing TGF-β1 concentrations of 10ng/ml vs. 20ng/ml, 
Figure 2A and 2C). 
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Figure 2 – Results of relative mRNA quantification obtained using qRT-PCR technique of 
epithelial and mesenchymal markers of MCF 7AZ cells treated with different concentrations 
of TGF-β1. A. CDH1 gene (epithelial marker) exhibit a decreased expression in cells treated with 
TGF-β1 independently of the concentration used. CDH2 (B), Vim (C) and FN1 (D) genes 
(mesenchymal markers) also display decreased expression with the increase of TGF-β1 
concentration. Asterisk stands for significant comparisons (p<0.05). 
 
 
Several attempts were made to induce EMT on MCF7AZ cells, varying different culture 
conditions, such as the confluence state of cells (data not shown). The results obtained 
were similar to those presented previously. 
 
The results described lead us to believe that MCF7AZ was not an EMT inducible cell line, 
at least not with TGF-β1 as an EMT driver. For this reason we did not perform any other 
experiments with this cell line. 
1.2 Near-normal cell line MCF10A 
We followed the same strategy described previously to assess the best adequate TGF-β1 
concentration to induce EMT in the MCF10A cell line. Unlike MCF7AZ cells, we were able 
to induce EMT in MCF10A cells, as indicated by bright field microscopy (Figure 3). The 
morphological alterations upon TGF-β1 treatment (both 10 and 20 ng/ml) point to the 
successful EMT occurrence.  
Alterations of protein expression/localization were also detected by co-
immunofluorescence for E-cadherin and Vimentin (Figure 3). Cells cultured withoutTGF-
β1 added, displayed expression of E-cadherin at the cell membrane. However, this pattern 
of expression was lost  
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Figure 3 – Effect of distinct TGF-β1 concentrations on EMT induction in MCF10A cell line. 
The cells were treated with different concentrations of TGF-β1 (0, 10 and 20 ng/ml) in order to 
induce EMT. For each condition is represented a bright field microscopy image (100x) and a co-
immunofluorescence for E-cadherin (green) and Vimentin (red). The white scale bar corresponds to 
50 µm. When cells were treated with 10 and 20 ng/ml of TGF-β1, E-cadherin lost its typical 
expression and fibers of Vimentin were formed. The white scale bar corresponds to 50 µm. 
 
 
in cells cultured with both 10 and 20 ng/ml of TGF-β1 and was replaced by a strong 
expression of Vimentin forming well defined fibers. 
Next, we evaluated the expression of epithelial and mesenchymal markers by qRT-PCR 
on MCF10A cells cultured with distinct concentrations of TGF-β1. 
 
 
 
Figure 4 –Relative mRNA quantification of epithelial and mesenchymal markers in MCF10A 
cells treated with different concentrations of TGF-β1.A.CDH1 gene (epithelial marker) exhibit a 
decreased expression in cells treated with TGF-β1 independently of the concentration used. 
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CDH2(B), Vim(C) and FN1(D) genes (mesenchymal markers) display a trend to increase its 
expression with the increase of TGF-β1 concentration. Asterisk stands for significant comparisons 
(p<0.05). 
 
The results confirmed that MCF10A effectively underwent EMT. We observed that 
CDH1significantly decreased when MCF10A cells were cultured with 10 and 20 ng/ml of 
TGF-β1 (p-value=4,52E-10 and p-value=5,02E-07 in comparison with no TGF-β1 added, 
Figure 4A). Concerning the mesenchymal markers: 1) CDH2 significantly increased when 
cells were cultured with 10 and 20 ng/ml of TGF-β1 (p-value=1,73E-07 and p-
value=1,69E-08, in comparison with no TGF-β1 added, Figure 4B); 2) Vim also had a 
significant increase when cells were cultured in the presence of 10 and 20 ng/ml of TGF-
β1 (p-value=7,63E-09 and p-value=3,83E-09, in comparison with no TGF-β1 added, 
Figure 4C)and; 3) similar to CDH2 and Vim, FN1 also significantly increased with 10 and 
20 ng/ml of TGF-β1 being added to the culture medium (p-value=7,71E-10 and p-
value=3,19E-09, in comparison with no TGF-β1 added, Figure 4D).The three 
mesenchymal markers tested also showed a significant increase when comparing the 
results of culture with 10 ng/ml with 20 ng/ml, indicating a dose-dependent expression (p-
value=7,30E-05, 6,74E-06, 6,62E-05 for CDH2,Vim andFN1 when comparing TGF-β1 
concentrations of 10ng/ml vs. 20ng/ml, Figure 4B-D). No dose-dependent expression was 
observed for CDH1 expression. 
Given that both TGF-β1 concentrations efficiently induced EMT on MCF10A cells, as 
confirmed by the significant alterations detected for all markers tested, we selected the 
lowest concentration (10 ng/ml) for the subsequent experiments. We have also renamed 
MCF10A cells after TGF-β1 treatment as Mesenchymal MCF10A cells (M cells).Since our 
results supported the occurrence of EMT in MCF10A cells, we used only this cell lineto 
perform the EMT reversion. 
 
2. MET, THE RECOVERY OF THE EPITHELIAL PHENOTYPE? 
We reproduced again the EMT process using only the chosen concentration of TGF-β1 
(10ng/ml) in order to obtain mesenchymal MCF10A cells (M cells).As expected, we 
observed an acquisition of a spindle-shaped morphology (bright field microscopy images), 
the loss of the typical expression of E-cadherin (IF) and the formation of Vimentin fibers in 
M cells indicating that EMT had occurred. Next, we continued to grow M cells in culture 
medium, deprived of TGF-β1. The culture of M cells was interrupted when bright field 
microscopy images pointed towards a recovery of an epithelial phenotype. These post-
EMT epithelial-like MCF10A cells were renamed as transient state cells (TS cells, Figure 
6). In fact, as displayed in Figure 5, bright field microscopy images of TS cells showed a 
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partial recovery of epithelial features. In addition, by immunofluorescence, we observed 
that E-cadherin expression was recovered to some extent at the cell membrane (Figure 
3). Regarding the expression of Vimentin (Figure 5), by immunofluorescence it was 
possible to observe that the fibers formed in M cells were lost in TS cells: in fact, the 
pattern of Vimentin expression observed in E cells was recovered in TS cells. 
 
Figure 5 –MET, the recovery of the epithelial phenotype after the removal of TGF-β1 from the 
culture medium. M stands for mesenchymal cells and TS stands for transient state cells. Bright 
field microscopy images showing the recovery of the cobble-shaped phenotype of cells (100x). The 
re-expression of E-cadherin at the cell membrane can be observed by immunofluorescence (IF). 
The loss of Vimentin expression is evident when comparing M with TS cells by 
immunofluorescence. The white scale bar represents 50 µm. 
 
Facing these results it was our conviction that our in vitro model successfully mimicked 
EMT which was then successfully reverted indicating the occurrence of MET. 
 
3. THE ESTABLISHMENT OF A HUMAN IN VITRO EMT/MET MODEL 
We have successfully created an in vitro model of EMT and MET, using the human 
epithelial cell line MCF10A (Figure 6). Figure 6 summarizes the alterations in morphology 
and in protein expression/localization of MCF10A cells through the three steps of 
EMT/MET: E cells, the original cell line; M cells, upon EMT induction and; TS cells, 
generated after MET (or partial MET) occurrence. 
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By immunofluorescence, we observed a significant loss of E-cadherin expression in M 
cells, later recovered in TS cells (Figure 6). Concerning Vimentin expression, 
immunofluorescence revealed an altered pattern of expression, exclusively in M cells 
which displayed well defined fibers, in line with EMT occurrence (Figure 6).  
 
Figure 6 – EMT/MET model validation. Bright field microscopy images showing the phenotypical 
alterations and co-immunofluorescence for E-cadherin and Vimentin during EMT/MET induction 
(100x). E stands for epithelial cells, M stands for mesenchymal cells and TS stands for transient-
state cells. E cells lose the cobble-shaped phenotype to become M cells and a partial recovery of 
the cuboid phenotype occur in TS cells. In the co-immunofluorescence images M cells lose the E-
cadherin expression at the cell membrane and acquire a filamentous expression of Vimentin. TS 
cells recover some expression of E-cadherin and lose Vimentin expression. The white scale bar 
represents 50 µm.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 – Protein expression of epithelial and mesenchymal markers during EMT and MET 
(one biological replicate). Results of the Western Blot performed for E-cadherin (A), β-catenin 
(B), Fibronectin (C) using total protein lysates extracted from E, M and TS cells from the in vitro 
model of EMT/MET using MCF10A cells. D. Quantification of the bands present in A, B and C.E-
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cadherin expression decreased during EMT; β-catenin displayed similar levels in all cells and only 
M cells expressed Fibronectin.  
 
We next ran a preliminary assay to evaluate the protein expression of epithelial and 
mesenchymal markers in the EMT/MET model (Figure 7). Concerning the epithelial 
markers: 1) E-cadherin had a decreased expression during EMT and no recovery of its 
expression was observed by Western Blot (Figure 7A and 7D) and; 2) the expression of 
β-catenin was constant across EMT and MET (Figure 7B and 7D). Regarding the 
mesenchymal marker Fibronectin, its expression was absent in E and TS cells, being only 
expressed in M cells (Figure 7C and 7D). 
We also evaluated the mRNA expression of a panel of epithelial (CDH1 and Ocln) and 
mesenchymal (FN1 and Vim) markers, as well as an EMT inducer (Zeb2). Regarding the 
epithelial markers: 1) CDH1 had a significant decrease of expression in M cells (p-
value=3,66E-04, in comparison with E cells, Figure 8A) and a significant increase in TS 
cells (p-value=1,73E-04, in comparison with M cells, Figure 8A), recovering almost the 
same expression levels of E cells and; 2) Ocln had the same behavior as CDH1, with 
significant decrease of expression during EMT(p-value=4,74E-06, in comparison with E 
cells, Figure 8B) and a recovery of expression during MET(p-value=4,97E-06, in 
comparison with M cells, Figure 8B). Concerning the mesenchymal markers/EMT 
inducers: 1) FN1 gene had an evident and significant increase of expression during EMT 
(p-value=5,23E-07, comparing E with M cells, Figure 8C) and significantly decreased 
almost recovering to its basal levels of expression during MET (p-value=1,44E-04, 
comparing M with TS cells, Figure 8C);2) interestingly, Vim expression did not vary with 
EMT and significantly increased with MET (p-value=8,66E-03, comparing M with TS cells, 
Figure 8D), unlike expected of a mesenchymal marker. In addition, TS cells displayed 
increased levels of Vim in comparison with E cells (p-value=7,60E-03, Figure 8D) and; 
3)the EMT inducer Zeb2expression significantly decreased during EMT (p-value=7,35E-
05, comparing E with M cells, Figure 8E) while during MET its expression significantly 
increased (p-value=3,68E-04, comparing M with TS cells, Figure 8E).  
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Figure 8 – Relative mRNA quantification of Epithelial and Mesenchymal markers and an EMT 
inducer (one biological replicate).A.CDH1revealed a trend to decrease with EMT and to increase 
with MET. B. Ocln exhibited a decreased expression with EMT and increased with MET. C. Vim 
had a slight increase with EMT and also increased with MET. D.FN1 massively increased with EMT 
and decreased with MET.  E.Zeb2 decreased with EMT and increased with MET. Asterisk stands 
for significantly comparisons (p<0.05). 
 
The cell lines, MCF10A and MCF7AZ, used to induce EMT and MET with TGF-β1, did not 
present the same results. Although several attempts at EMT were made, MCF7AZ cell 
line was excluded because it did not exhibit any of the features that were expected after 
TGF-β1 treatment. Nevertheless, MCF10A cells cultured with TGF-β1,displayed classical 
phenotypical alterations, decreased expression of epithelial markers and concomitant 
increase in the expression of mesenchymal markers, clearly pointing towards the 
occurrence of EMT and a subsequent reversion of this process, MET. 
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DISCUSSION 
 
The aim of this part of the work was to establish an in vitro EMT/MET model using the cell 
lines selected in Chapter One, MCF10A and MCF7AZ, using TGF-β1 as an EMT inducer. 
The first step to accomplish this aim was to define the best suited concentration of TGF-
β1 needed to successfully induce EMT. Both cell lines were treated with 10 or 20 ng/ml of 
TGF-β1. In literature many different concentrations of TGF-β1 have been described, 
ranging from 2 to 20 ng/ml [35]. We decided to use 20 ng/ml to assure that cells were 
given enough TGF-β1 to undergo EMT (top limit in several published studies). The second 
concentration of TGF-β1 used (10 ng/ml) was selected given that it is one of the most 
common concentrations used to induce EMT according to several studies [36]. MCF7AZ 
cell line treated with both concentrations of TGF-β1 did not present alterations in its 
morphology and in the expression/localization of E-cadherin and Vimentin. Regarding the 
RNA expression levels of epithelial and mesenchymal markers tested, the only marker 
that could indicate the occurrence of EMT was CDH1:CDH1displayed a significant 
expression decrease when MCF7AZ cells were cultured with both concentrations of TGF-
β1 in comparison with no TGF-β1 added to the culture medium. Despite the decrease of 
expression of CDH1, the expression of E-cadherin at the cell membrane did not suffer any 
alteration. We performed several other attempts, varying different culture conditions; 
however we were never able to successfully induce EMT in MCF7AZ cells (data not 
shown). Facing these results we decided to exclude this cell line from our study. 
MCF10A cell line displayed several alterations that were expected in the case of 
successful TGF-β1-induced EMT: 1) acquisition of a spindle-shaped morphology; 2) loss 
of the typical membrane expression of E-cadherin; 3)formation of well-defined Vimentin 
fibers, a classical mesenchymal feature [31]; 4)decreased CDH1 expression and; 
5)increased CDH2, Vim and FN1 expression. In addition, mesenchymal markers showed 
a dose-dependent expression since the expression of CDH2, Vim and FN1 was 
significantly higher when cells were cultured with 20 ng/ml of TGF-β1(in comparison with 
10 ng/ml).Our results combined with the fact that most TGF-β1-induced-EMT studies use 
10 ng/ml of TGF-β1, lead us to select this concentration for the subsequent inductions 
with the MCF10A cell line. 
 
As a second task of this part, we wanted to reverse the EMT process in MCF10A cells. 
We first reproduced the EMT step thus creating 2 individual cell populations: E cells, 
corresponding to epithelial cells (the parental MCF10A cell line), and M cells, 
corresponding to mesenchymal cells (obtained after EMT had occurred). Next, we 
removed TGF-β1 from the culture medium and M cells recovered a near-epithelial 
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morphology, thus creating a third cell population, which we denominated as transient-state 
(TS) cells. When TGF-β1 was removed from the culture medium, TS cells displayed: 1) a 
phenotype similar to that of E cells, recovering the cobble-shaped morphology; 2) 
expression of E-cadherin at the cell membrane, again as in E cells; 3) less presence of 
Vimentin fibers, most visible in M cells; 4) recovery of CDH1 and Ocln expression and; 4) 
loss of FN1expression. Concerning Vim, and in this particular biological replicate, RNA 
expression did not reproduce the behavior of a classical mesenchymal marker. Despite 
this unexpected finding, the immunofluorescence images clearly showed that M cells 
displayed Vimentin protein expression organized in well-defined fibers, unlike E or TS 
cells. Such fiber-like pattern is typical of mesenchymal-like cells and demonstrate partial 
recovery of an epithelial-like phenotype in TS cells.  
The results concerning Zeb2, are very preliminary and were not clear: unlike most in vitro 
EMT models, our MCF10A model exhibited decreased expression in M cells. However, 
this observation was only made at the RNA level, given that we did not evaluate Zeb2 
protein expression. In fact, Zeb2 protein is increased upon EMT due to the existence of a 
post-transcriptional mechanism via an Internal Ribosome Entry Site (IRES) necessary for 
its translation. Therefore, Zeb2 RNA levels are not necessarily related to Zeb2 protein 
expression [37]. 
As final conclusion of this chapter, it is reasonable to state that we successfully created a 
human in vitro EMT/MET model that can be explored to evaluate regulatory pathways. 
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CHAPTER THREE 
How to explore regulatory functions with this EMT/MET model  
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AIM 
 
The aim of this Chapter was to demonstrate some applications of the previously described 
TGF-β1-induced EMT/MET model using the MCF10A cell line. Here we present some 
interesting parallels between the MCF10A EMT/MET in vitro model and another similar 
model previously established by our group (EpH4 EMT/MET in vitro model) [22]. The 
results herein presented are part of ongoing work. 
 
RESULTS 
 
1. DIES1, A KEY GENE FOR MOUSE EMBRYONIC STEM CELL DIFFERENTIATION VARY ALONG 
EMT/MET 
A recent study by Aloia et al2010 has pinpointed Dies1 (Differentiation of Embryonic Stem 
Cells 1) as a relevant gene for the differentiation process of mouse embryonic stem cells 
(mESCs)[38].Given that EMT is a dedifferentiation phenomenon [39] – we have 
hypothesized thatDies1could have a role in EMT/MET. Preliminary studies on an in vitro 
model, established by our group, ofTGF-β1-induced EMT/MET using the near-normal 
murine EpH4 cell line[22] has strengthen our hypothesis: Dies1 expression was 
significantly decreased in EMT and recovered upon MET to levels above those observed 
in the parental cell line, in concomitance with Dies1 promoter demethylation. Therefore, 
we analyzedDies1 expression and promoter methylation in MCF10A E, M and TS cells. 
We observed thatDies1 had a significant decreased expression during EMT (p-
value=7,46E-06, comparing E and M cells, Figure 1A) and was significantly increased 
during MET (p-value=3,56E-06, comparing M and TS cells, Figure 1A). Interestingly, 
Dies1 expression also displayed a significant increase when comparing E with TS (p-
value=9,17E-04, Figure 1A). These results reproduced completely the ones previously 
observed for EpH4 cells. 
 
Aloia et al (2010) have also observed an involvement of Dies1 in the BMP signaling 
pathway. Therefore, we next analyzed the expression of effectors of the BMP pathway,Id2 
and Id3. We observed thatId2expression was significantly lower in M cells (p-
value=1,02E-06, comparing with E cells, Figure 1B) and had a significant increase in TS 
cells (p-value=1,49E-05, comparing with M cells, Figure 1B). Concerning Id3, we 
observed a significant decrease during EMT (p-value=1,21E-03, comparing E with M cells, 
Figure 1C) and in MET (p-value=2,89E-02, comparing M with TS, Figure 1C).  
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Figure 1 - Relative mRNA quantification of Dies1 (A), Id2 (B) and Id3 (C) during EMT and 
MET. Significant variations were detected for all genes (asterisk stands for p<0,05). 
 
As Dies1 mRNA expression followed, in MCF10A, the same trend we observed in EpH4, 
we reasoned that the mRNA expression decreased in the M state could also be explained 
by promoter methylation. Then, we proceeded by evaluating the methylation status of 
Dies1 promoter in MCF10A EMT/MET model. Previous studies by our group predicted the 
presence of a CpG island in the vicinity of the humanDies1gene (chromosome 10: 
73533894-73534693) and 40 CpG sites were evaluated (chromosome 10: 73534292-
73534425). Despite all efforts, we were able to observe that Dies1 promoter was 
demethylated both in E and TS cells, but the Dies1 methylation status in M state, was 
impossible to assess due to technical difficulties. 
 
 
Figure 2 – Result of the evaluation of the methylation status of the Dies1 promoter of 
MCF10A E and TS cells (one biological replicate). Circles represent individual CpG sites 
assessed. Black circles stand for methylated CpG sites; gray circles for partially methylated CpG 
sites; white circles for unmethylated CpG sites and; dashed white circles for CpG sites not 
assessed. 
77 
 
DISCUSSION AND UNANSWERED QUESTIONS 
 
The creation and validation of the MCF10A EMT/MET model, extensively described in the 
previous Chapters, enabled us to go one step beyond and establish parallels with an 
already published EMT/MET model by our group. Using the near-normal murine EpH4 cell 
line and TGF-β1 as inducer, we were earlier able to create three distinct cell populations, 
similarly to the MCF10A in vitro EMT/MET model: EpH4-E, EpH4-M and EpH4-TS cells 
[22]. The later three cell populations were subjected to whole transcriptome sequencing 
(Illumina Genome Analyzer, RNAseq) and more than 4000 differentially-expressed genes 
were detected. At the same time the study by Aloia et al (2010) was published, revealing 
an intriguing relationship between the recently annotated geneDies1 and mESCs 
differentiation. Knowing that EMT is a dedifferentiation phenomenon [39], we 
hypothesized whetherDies1 could have a relevant role in EMT/MET. Using the RNAseq 
data produced, we observed a significant variation of Dies1 expression with EMT/MET in 
our previous model: Dies1 was significantly downregulated with EMT and greatly 
increased upon MET. In fact, EpH4-TS cells, generated after the differentiation process of 
MET, displayed massive amounts of Dies1. These results, validated by qRT-PCR in 
distinct biological replicas, strengthened our hypothesis of Dies1 involvement with 
EMT/MET. In light of the aim of this part of the study, we assessed Dies1 expression in 
MCF10A E, M and TS cells: results similar to those described for EpH4 E, M and TS cells 
were observed, which may indicate a consistent behavior of Dies1 in both EMT/MET 
models. However, Dies1 promoter methylation status was different when comparing the 
MCF10A EMT/MET with EpH4 EMT/MET model: while Dies1 promoter methylation status 
varied during Eph4 EMT/MET, no variation was observed in the MCF10A EMT/MET. In 
addition, we could not assess the Dies1 promoter methylation status of MCF10A M cells. 
The study by Aloia et al had also shown an involvement of Dies1 with the BMP signaling 
pathway. In fact, the authors had shown that upon Dies1downregulation in mESCs, the 
BMP signaling cascade was greatly decreased, an observation supported by: 1) 
decreased expression of Id1, Id2 and Id3, downstream effectors of the BMP pathway; 2) 
decreased activity of Id1 gene promoter and; 3) reduced phospho-Smad1 levels. This 
study also showed thatDies1 knock-down (and the consequent BMP pathway 
downregulation), led to maintenance of mESCs in an undifferentiated state [38]. 
Therefore, we evaluated the expression of Id1 (by RNAseq), Id2 and Id3(by RNAseq and 
qRT-PCR) in the EpH4 EMT/MET model: EpH4-TS cells displayed increased Id2 and Id3 
expression, both in comparison to EpH4-E and EpH4-M cells. No expression variation 
was detected for Id1.These results pointed towards an over-activation of the BMP 
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pathway in EpH4-TS cells in concomitance with Dies1 expression. Concerning the 
MCF10A EMT/MET model, we have only evaluated Id2 and Id3expression by qRT-PCR. 
We have observed that both Id2 and Id3 expression significantly decreased upon EMT 
and only Id2 revealed a small recovery upon MET. This expression variation was distinct 
to that observed in the EpH4 EMT/MET model. 
Although both EpH4 and MCF10A were EMT/MET induced using a similar strategy, it is 
necessary to take into account that the two models differ in several aspects: 1) EpH4 cell 
line derives from mouse mammary gland while MCF10A cell line has a human origin; 2) 
EpH4 TS cells displayed an heterogeneous pattern of epithelial and mesenchymal 
markers unlike the extremely homogenous population of MCF10A TS cells and;3) unlike 
MCF10A M cells, EpH4 M cells did not display a decreased CDH1/E-cadherin expression. 
Concerning this last observation, our study has shown that in EpH4 M cells, E-cadherin, 
although present, exhibited loss of functionality due to incorrect post-transcriptional 
modifications, in particular, incorrect glycosylation [22]. The differences observed in both 
EMT/MET models only highlighted the relevance of the similarities found: common events 
will be of relevance for the study of EMT/MET, regardless of the context, or in this case, of 
the cell line used. This fact only stresses the importance of Dies1 expression variation 
during EMT/MET, found to be common between both models. Further studies are 
currently ongoing, such as Dies1 expression inhibition and its consequences on 
EMT/MET occurrence. 
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SUMMARY AND CONCLUSIONS 
 
In this Thesis, we generated data that match, in its majority, our general aim: we 
established and characterized a human in vitro model of EMT and MET. We have started 
by characterizing a series of human near-normal mammary cell lines: HB4a, 226Land 
MCF10A. This characterization, described in Chapter One of this Thesis, aimed at 
selecting the most adequate cell line to induce EMT and MET, two normal occurring 
biological processes of significance in cancer initiation/progression. This characterization 
encompassed RNA and protein expression analysis using qRT-PCR, 
immunofluorescence and western-blot of both epithelial and mesenchymal markers. The 
combined analysis of this characterization, together with existing literature data, led to the 
choice of MCF10A as a suited model for EMT/MET induction. Given the link between EMT 
and cancer progression, we have also characterized and used a human cancer-derived 
mammary cell line, MCF7AZ, for EMT/MET induction as a pathological counterpart of 
MCF10A. 
 
After the appropriate cell line selection, we proceeded by testing several conditions to 
induce EMT in both MCF10A and MCF7AZ cell lines. We were able to successfully induce 
EMT in MCF10A cells, a fact confirmed by the loss of expression of several epithelial 
markers and de novo expression of mesenchymal markers. The same was not valid for 
MCF7AZ cells, a task that was later on abandoned, despite several attempts as described 
in Chapter Two of this Thesis. After adequate confirmation of EMT occurrence in the 
newly created MCF10A M cells, we successfully accomplished the second aim of our 
work: MET induction. The MCF10A TS cell population created was also extensively 
characterized and confirmed the occurrence of MET, with expression recovery of several 
epithelial markers and concomitant loss of mesenchymal markers. 
 
The relevance of this newly created MCF10A EMT/MET model was also assessed by 
comparison with another model, previously created by our group, using a distinct near-
normal cell line (EpH4 of murine origin).Chapter Three presented some preliminary 
results concerning a recently annotated gene (Dies1), which revealed both similarities and 
differences among the two EMT/MET models. While the differences may be due to distinct 
features of each cell line, the similarities emphasized EMT/MET general characteristics 
and strengthen the general aim of this Thesis, which was to create novel EMT/MET in 
vitro models. 
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FUTURE PERSPECTIVES 
 
Although many studies have been published concerning EMT and cancer progression, 
few focus on MET and its relevance, particularly in metastization. The extensive 
characterization described in this Thesis has provided the backbone for future studies, 
such as: 
 
 Expression analysis of key elements of several biological pathways such as 
PI3K/mTOR/AKT signaling pathway and Wnt signaling pathway. Data from the 
RNAseq performed on the EpH4 EMT/MET model pointed towards a differential 
activation of these (and other) pathways. 
 
 Expression analysis of microRNAs in MCF10A E, M and TS cells as well as their 
corresponding conditioned mediums. Preliminary data pointed towards a 
differential expression of several microRNAs, which could impact the expression of 
several other target molecules. 
 
 Evaluation of the differential tumorigenic/metastization potential of MCF10A E, M 
and TS cells using in vivo assays. EpH4 E, M and TS cells have been previously 
injected into the mammary fat pad of nude mice and preliminary results have 
pointed towards an increased tumorigenic ability of EpH4 TS cells. In addition, all 
three types of cells were injected into the tail vein of nude mice (a classical 
metastization assay) and increased lethality has been associated specifically with 
EpH4 TS cells. 
 
 
These and other studies are currently ongoing and highlight the relevance of the work 
described in this Thesis. 
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